Pharmaceuticals, Biotechnology and Life Sciences
Roche said Tuesday it started testing Actemra (tocilizumab) with the Biomedical Advanced Research and Development Authority (BARDA)on top of standard of care in hospitalised adult patients with severe COVID-19 pneumonia compared to placebo on top of standard of care.
AMryt gave an update of its business, and it included a reflection of the COVID-19 pandemic effect on its projects.…
Secarna Pharmaceuticals has signed a Research, Development and Transfer Agreement with Lipigon Pharmaceuticals AB (Lipigon), in which Lipigon will get certain antisense drug candidates, which were developed with Secarna’s proprietary LNAplus platform, including the corresponding patent portfolio.
ObsEva CEO Ernest Loumaye s said the instituting new measures to support the priorities of safety to manage through the COVID-19 pandemic.
The Pharma & Biopharma Outsourcing Association (PBOA), a trade group that represents Contract Manufacturing Organizations (CMOs) and other service providers…
The U.S. Food and Drug Administration is actively and aggressively monitoring the market for any firms marketing products with fraudulent coronavirus (COVID-19) diagnostic, prevention and treatment claims as part of our ongoing efforts to protect public health during this pandemic. As a result of these activities, the agency is beginning to see unauthorized fraudulent test kits that are being marketed to test for COVID-19 in the home.
Oxford Biomedica has signed a new Licence and Clinical Supply Agreement (LSA) with Bristol-Myers Squibb’s company, Juno Therapeutics to use Oxford Biomedica’s LentiVector platform for its application in CAR-T and TCR-T programmes in oncology and other indications.
Merck said on Tuesday it got top-line efficacy results from two its pivotal Phase 3 trials (COUGH-1 and COUGH-2) testing…
Pfizer and BioNTech on Tuesday said they have executed a Material Transfer and Collaboration Agreement to enable the parties to immediately start working together on a potential mRNA-based coronavirus vaccine for preventing COVID-19 infection.
BioNTech SE said Monday its development a potential vaccine to induce immunity and prevent COVID-19 infection in response to the growing global health threat posed by the disease has seen rapid progress. BioNTech’s product candidate, BNT162, is a potential first-in-class mRNA vaccine in the worldwide effort against COVID-19.